ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC

Inclusion Criteria: * Histologically confirmed stage IIIB/IV NSCLC; * Histologically confirmed adenocarcinoma; * EGFR-wildtype NSCLC; * Provision of blood (plasma) sample for ctDNA testing; * Patient must be able to comply with the protocol; * Provision of blood (plasma) sample for ctDNA testing; Exclusion Criteria: * As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease); * Histologically confirmed small cell lung cancer or other metastatic tumors; * Patient with no histologic or cytological diagnosis;